drugset / Trial / NCT02191475

Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock

NCT02191475

RandomizedParallel-groupSingle-blindTreatment

Summary

Selection of tigecycline in severe sepsis and septic shock patients in empirical antibiotic therapy (Hai Zheng Energy Star ®) combined with piperacillin / tazobactam (tazocin ®) scheme, compared with the classical scheme, evaluate its efficacy, safety index.

Timeline

Start
2014-05
Primary completion
2017-05
Completion
2017-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Linezolid Other / unclassified 300 mg Intravenous
Comparator Meropenem Small molecule 1 g Intravenous
Subject Tigecycline Small molecule 50 mg
Comparator Vancomycin Other / unclassified 15 mg/kg Intravenous
Comparator imipenem/cilastatin Unknown 500 mg Intravenous
Subject piperacillin/tazobactam Other / unclassified 4.5 g Intravenous